As reported by the recent VISION trial, PSMA-targeted therapy with [177Lu]Lu-PSMA-targeting radiopharmaceuticals provided excellent results in metastatic castration-resistant prostate cancer patients [22]. The gene discussed is FOLH1; the disease is prostate cancer.